NCT04274816View on ClinicalTrials.gov

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 10, 2012

Primary Completion Date

February 27, 2014

Study Completion Date

February 27, 2014

Conditions
Cutaneous Melanoma
Interventions
DRUG

Tremelimumab

Intradermal injection of tremelimumab 7 days prior to sentinel node biopsy, with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).

All Listed Sponsors
lead

A.J.M. van den Eertwegh

OTHER

NCT04274816 - Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma | Biotech Hunter | Biotech Hunter